CNQ · BETR.CN
BetterLife Pharma Inc.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
Loading market information…
CNQ · PHRM.CN · CAD
Stock price, earnings
Quote as of Oct 28, 2026, 08:44 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
PharmaTher Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PharmaTher Holdings Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
CA$0.16CA$0.00 (0.0%)
Pharmala Biotech Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.52% below the high.
CA$0.04CA$0.00 (0.0%)
AI/ML Innovations Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.94% below the high.
CA$0.12CA$0.00 (0.0%)
Marvel Biosciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 52.0% below the high.
CA$0.04CA$0.00 (0.0%)
Glow Lifetech Corp.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
CA$0.02+CA$0.01 (+50.0%)
Blueberries Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 25.0% below the high.
CA$0.03CA$0.00 (0.0%)
Christina Lake Cannabis Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
$0.09$0.00 (0.0%)
BioVaxys Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.73% below the high.
